A 12-week randomized, placebo controlled phase II study of AZD-9668 for the treatment of alpha-1 antitrypsin deficiency (AATD)
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2018
At a glance
- Drugs Alvelestat (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Proof of concept; Therapeutic Use
- Sponsors Mereo BioPharma
- 23 Mar 2018 According to a Mereo BioPharma media release, the company intends to initiate this study in the second half of 2018.
- 04 Nov 2017 New trial record
- 30 Oct 2017 According to a Mereo BioPharma media release, the company intends to initiate this study in 2018.